Scholars Central

Conference abstractPublished 15 Jul 2013

MicroRNAs involve inhibition of tumor progression by NSAIDs

Authors: Yaguang Xi

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Although mechanisms of the action have yet been well-understood, non-steroidal anti-inflammatory drugs (NSAIDs) are widely reported to display strong efficacy for cancer prevention. The most known anti-cancer activities of NSAIDs include inhibition of tumor cell proliferation and induction of apoptosis, but their effects on tumor progression and metastasis have not been well studied. Here, we show that the NSAID, sulindac sulfide (SS) can potently inhibit the invasion of human MDA-MB-231 breast and HCT116 colon tumor cells in vitro at concentrations less than those required to inhibit tumor cell growth. When studying the molecular basis for this activity, we found that SS can inhibit the translocation of NF-κB to the nucleus by decreasing the phosphorylation of IKKβ and IκB. NF-κB is one of the most known transcription factors and regulates expression of numerous genes including microRNAs. After we explored the global microRNA profile of HCT116 tumor cells by using microarray analyses, a total of 132 microRNAs were found to be altered (17 up and 115 down) in response to SS treatment, including miR-17-92 cluster, miR-10b, miR-21 and miR-9, which have been previously implicated in tumor progression and metastasis. Our data show that these microRNAs can significantly promote tumor cell invasion but SS can inhibit these oncogenic activities by suppressing their expression at transcriptional level. Analysis of the promoter sequences of 115 microRNAs suppressed by SS revealed that 81 of them contained NF-κB-binding sites. Employing chromatin immunoprecipitation (ChIP) assays, we confirmed that NF-κB could bind the promoters of miR-17-92 cluster, miR-10b, miR-21 and miR-9. In addition to validation of several published metastatic suppressors targeted by these microRNAs, such as TβR, HOXD10, TPM1, and PDCD4, we identified a novel marker QKI that is co-targeted by these oncogenic microRNAs and responsible for the inhibitory effect on tumor cell invasion by SS. In summary, our results show that microRNAs and their target genes involve inhibition of tumor progression by the NSAID sulindac.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Molecular Biomarkers & Diagnosis.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Molecular Biomarkers & Diagnosis
  • SubjectGenetics & Molecular Biology
  • SubjectPathology & Lab Medicine
  • BylineArticles whose byline prints “Yaguang Xi”